Cantargia has announced that it has completed recruiting patients (n=102) for the randomised Phase I...
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 10 mars 2025 att Bolaget har förlängt samar...
Redeye returns with an update following Alzecure's Q4 report.
Redeye updates on Maximum Entertainment following Q4-results which saw softer topline than expected ...
Redeye leaves a short comment on WntResearch’s extraordinary general meeting.
Safello has announced it intends to launch of exchange-traded products (ETPs), a pivotal step to div...
Systemair överraskar med en stark organisk tillväxt på 5,4 procent under det tredje kvartalet, övert...
ODI Pharma AB:s (”ODI Pharma” or the ”Company”) past two quarters has been affected by import restri...
Q4: DKK 155m SDR impairment, adj. EBIT slightly better vs.
Redeye endorses Ortoma’s received CE certification for OTS Hip Guide in accordance with MDR.
Organic sales decline of 12% y-o-y EBIT margin of 2.
Redeye comments on the announcement of a SEK34.1m rights issue of shares.
IRLAB Therapeutics has announced top-line results from the Phase IIb REACT-PD study evaluating its s...
Tura Group redovisade ett bra avslut på 2024. Omsättningsmässigt redovisades totala intäkter om 236 ...
Guiding for higher organic growth and margin expansion in 2025e Acquisition of Sounding Board should...
